Conservative surgery not inferior to nephrectomy

Apr 19, 2010

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary EAU Congress, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.

"Few patients progressed during the study, nine in the radical arm and 12 in the conservative arm," Prof. Hein van Poppel said in his concluding remarks. Van Poppel issued the EORTC results during the plenary session on , a study which examined partial versus radical nephrectomy in .

The EORTC 30904 study involved 541 patients who were randomised, 273 in the radical arm and 268 treated with conservative surgery. Four patients were clinically ineligible, whilst 139 patients were pathologically ineligible. The median follow-up was around 9.3 years.

Amongst the study's pertinent findings were:

  • Few patients progressed during the study, nine in the radical arm and 12 in the conservative arm
  • 117 deaths
12 due to RCC: 4 in radical and 8 in conservative

3 due to surgery: 1 in radical and 2 in conservative

  • Overall survival (OS) is shorter on the conservative arm for all randomized patients (p=0.032)
  • OS of RCC patients is not different (p=0.072)
  • OS of Clinically and pathologically eligible patients is not different (p=0.173)
  • Side effects: nephron-sparing surgery is safe with a slightly higher complication rate than after radical nephrectomy

Explore further: German Merck to buy St. Louis-based Sigma-Aldrich

Provided by European Association of Urology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

How less can be more when treating some kidney cancers

Jan 09, 2008

A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney ...

Recommended for you

German Merck to buy St. Louis-based Sigma-Aldrich

4 hours ago

German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.

The human race evolved to be fair for selfish reasons

Sep 19, 2014

"Make sure you play fairly," often say parents to their kids. In fact, children do not need encouragement to be fair, it is a unique feature of human social life, which emerges in childhood. When given the o ...

User comments : 0